Strategic consulting, powered by investments from an elite, expansive network.

Sasha Sinclair, CEO, is a strategic powerhouse with over a decade of experience leading $100M+ clinical trials for industry giants like Genentech & managing top tier hospitals globally. Her operational expertise and deep understanding of drug development position her to spot early-stage startups with the potential for massive market success and outsized returns.

With a sharp eye for scalable ventures, Sasha connects high-potential startups with the right investors from her elite funding network—offering founders critical capital and strategic guidance, and giving investors access to rare, vetted opportunities with the potential to significantly multiply their capital.

In addition to her biotech and startup advisory work, Sasha also leads real estate development and investment projects, bringing her same analytical rigor and long-term vision to physical assets that build wealth: Learn More

UltraAI

  • ULTRAai developed the first fully automated radiology workflow through unique patented AI technology, with the primary goal of leading safe automation in clinical radiology. 

    This technology can be used in other therapeutic areas such as pathology, dentistry, etc. 

  • -Aiming to raise $2-4M to complete the seed round. 

  • CareLink360® creates lasting connections by being the simplest, safest, and smartest way to connect seniors to family, friends, and care teams. In addition to video chat and photo sharing, every tap on the touch screen delivers health and wellness tools and education, medication and activity reminders, and lots of fun and lasting enjoyment. CareLink360® isn’t just technology; it’s a heart-to-heart connection, redefining how we care for those seniors who once cared for us.

  • -Aiming to raise $3M in growth capital to expand commercial team (In 12 countries currently). 

  • Novelna is at the forefront of biotechnology and AI, transforming cancer diagnostics. Our mission is simple: ensure early disease detection is not a privilege, but a right for all. By advancing diagnostic technologies, we are committed to securing a healthier and brighter future globally

  • -Aiming to raise $2M in bridge funding before starting Series A in Q3 2025.


  • We connect you with carefully selected investment opportunities that offer the potential for substantial returns. You’ll have access to high-growth ventures across biotech, real estate, and innovative startups, all backed by our exclusive network and rigorous vetting process.

  • We partner with you to streamline and optimize your operations, ensuring your business runs efficiently as you scale. Our expert team works with you to refine processes, improve workflows, and drive long-term operational success.

  • We offer tailored marketing strategies that increase visibility and drive engagement. With specialized services such as digitizing pitch decks, creating compelling ads and digital content, and writing press releases, we refine your presentation to ensure it speaks directly to investors and captures their attention—making your business exactly what they need to hear to invest.